摘要
过去30年，中国经济增速平均达到9．8％，综合国力由弱到强，人民生活逐步实现小康，国家和人民对健康保障需求日益增强，而2002年SARS的暴发是疫苗产业进入高速发展的催化剂。一类疫苗品种增多、利润下降，二类疫苗迅速崛起，多联、多价疫苗和新型疫苗点燃新的希望。
出处
《国际生物制品学杂志》
CAS
2012年第2期57-63,共7页
International Journal of Biologicals
参考文献11
-
1Skibinski DA,Baudner BC,Singh M. Combination vaccines[J].J Glob Infect Dis,2011,(01):63-72.doi:10.4103/0974-777X.77298.
-
2Hilleman MR. Vaccines in historic evolution and perspective:a narrative of vaccine discoveries[J].Vaccine,2000,(15):1436-1447.doi:10.1016/S0264-410X(99)00434-X.
-
3孟胜利.人用疫苗市场分析和展望[J].国际生物制品学杂志,2011,34(3):113-120. 被引量：2
-
4Food and Drug Administration. Complete list of vaccines licensed for immunization and distribution in the US[DB/OL].http://www.fda.gov/BiologicsBloodVaccines/Vaccines/Approved Products/UCM093833,2011.
-
5沈心亮.疫苗与抗体国内外研究进展[A]北京:中国生物技术集团公司,2011.
-
6Tregnaghi MW,Zambrano B,Santos-Lima E. Immunogenicity and safety of an investigational hexavalent diphtheria-tetanusacellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-,4-,and 6-month-old Argentinean infants[J].Pediatric Infectious Disease Journal,2011,(06):e88-e96.
-
7Su EL,Snape MD. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease[J].Expert Bev Vaccines,2011,(05):575-588.
-
8Mcintosh ED,Reinert RR. Global prevailing and emerging pediatric pneumococcal serotypes[J].Expert Review of Vaccines,2011,(01):109-129.doi:10.1586/erv.10.145.
-
9孟胜利,孙燕.流感疫苗市场现状与展望[J].生物技术世界,2009(6):64-66. 被引量：1
-
10Tate JE,Patel MM,Steele AD. Global impact of rotavirus vaccines[J].Expert Review of Vaccines,2010,(04):395-407.doi:10.1586/erv.10.17.
二级参考文献13
-
1Business Insights Ltd. The vaccines market outlook to 2014 [ R]. Woodbrook : Business Insights Ltd, 2009.
-
2Offit PA. Why are pharmaceutical companies grad ually abandoning vaccines? [ J ]. Health Aft ( Millwood ), 2005, 24(3) :622-630.
-
3Plotkin SA. Why certain vaccines have been delayed or not developed at all [ J ]. Health Aft (Millwood) , 2005, 24 (3) : 631 - 634.
-
4Kresse H, Shah M. Strategic trends in the vaccine market [J] .Nat Rev Drug Discov, 2010, 9(12) :913-914.
-
5Maggon K. Industrial R&D paradigm shift to vaccines [ J ] Biotechnol J, 2009, 4(4) :458-461. i.
-
6Muzumdar JM, Cline RR. Vaccine supply, demand, and policy: a primer [Jl. J Am Pharm Assoc (2003), 2009, 49(4) :e87-99.
-
7Kneller R. The importance of new companies for drug discovery: origins of a decade of new drugs [ J]. Nat Rev Drug Discov, 2010, 9(11) :867-882.
-
8Huggett B, Hodgson J, Lahteenmaki R. Public biotech 2009-- the numbers [J], Nat Biotechnol, 2010, 28(8) :793-799.
-
9Sheridan C. Fresh from the biologic pipeline--2009 [J], Nat Biotechnol, 2010, 28(4):307-310.
-
10Sheridan C. Vaccine market boosters [ J ]. Nat Biotechnol, 2009, 27(6) :499-501.
同被引文献13
-
1Lombard M,Pastoret PP,Moulin AM.A brief history of vaccines and vaccination[J].Rev Sci Tech,2007,26(1):29-48.
-
2D′Argenio DA,Wilson CB.A decade of vaccines:Integrating immunology and vaccinology for rational vaccine design[J].Immunity,2010,33(4):437-440.
-
3Nabel GJ.Designing tomorrow′s vaccines[J].N Engl J Med,2013,368(6):551-560.
-
4Rappuoli R,Aderem A.A 2020 vision for vaccines against HIV,tuberculosis and malaria[J].Nature,2011,473(7348):463-469.
-
5Koff WC,Burton DR,Johnson PR,et al.Accelerating nextgeneration vaccine development for global disease prevention[J].Science,2013,340(6136):1232910.
-
6Plotkin SA,Plotkin SL.The development of vaccines:how the past led to the future[J].Nat Rev Microbiol,2011,9(12):889-893.
-
7Taylor LH,Latham SM,Woolhouse ME.Risk factors for human disease emergence[J].Philos Trans R Soc Lond B Biol Sci,2001,356(1411):983-989.
-
8Bagnoli F,Baudner B,Mishra RP,et al.Designing the next generation of vaccines for global public health[J].OMICS,2011,15(9):545-566.
-
9Rappuoli R,Black S,Lambert PH.Vaccine discovery and translation of new vaccine technology[J].Lancet,2011,378(9788):360-368.
-
10Nasir A.Nanotechnology in vaccine development:a step forward[J].J Invest Dermatol,2009,129(5):1055-1059.
二级引证文献3
-
1朱安远,郭华珍.诺贝尔奖的风向标——美国拉斯克奖概览[J].中国市场,2016(5):183-194. 被引量：9
-
2刘晓欣,林瑞超,杨春宁,余世琪,张博.中国疫苗安全监管现状、问题及对策[J].中国公共卫生管理,2017,33(2):192-195. 被引量：33
-
3王兰,廖波,范回生,何文军,陈素华,宁晓屏.疫苗冷链管理的科学性和可操作性探讨[J].中国公共卫生管理,2021,37(2):180-182. 被引量：12
-
1不可忽略的健康保障[J].养生大世界,2005(10B):45-45.
-
2我国正在由疫苗使用生产大国转向研制强国[J].中国医药导报,2008,5(19):1-1.
-
3二类疫苗市场放开之后[J].制药原料及中间体信息,2005(7):44-45.
-
4赵铠.儿童疫苗的发展现状及趋势[J].中华医学信息导报,1997,0(21):2-3.
-
5王裕,郭兴萍,宋春英,史雅萍.生殖医学中心病案的科学管理[J].中国计划生育学杂志,2008,16(5):269-270. 被引量：3
-
6国家出版基金资助项目《新世纪心理与心理健康教育文库》开明出版社最新呈献[J].心理技术与应用,2015,0(10).
-
7我国疫苗批签发管理步入良性轨道[J].中国药事,2005,19(7):394-394.
-
8胡品选.慢生活利养生[J].养生月刊,2012,33(8):732-733.
-
9山东疫苗[J].中国家庭医生,2016,0(10):2-3.
-
10张晓萍.失眠的自我调节与综合治疗[J].中国实用医药,2009,4(2):209-210. 被引量：3
